methsuximide

Trade name: celontin

Small moleculeapproved

Approved

Feb 8, 1957

Mesuximide (or methsuximide) is an anticonvulsant medication. It is sold by Pfizer under the name Petinutin. Binds to T-type voltage sensitive calcium channels. Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the "low-voltage activated (LVA)" group and are strongly blocked by mibefradil. A particularity of this type of channels is an opening at quite negative potentials and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes. Mesuximide is used for the control of absence (petit mal) seizures that are refractory to other drugs. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 3 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Timeline

1950s

Feb 8, 1957
Earliest FDA Approval

2020s

May 1, 2023
Novitium Pharma — Marketing Organization
May 1, 2023
Ani Pharmaceuticals — Marketing Organization

Indications

Approved for

Mechanism of action

Voltage-gated T-type calcium channelBLOCKER
Voltage-gated T-type calcium channel blocker

Approval history

approvedPriority reviewFeb 8, 1957

Chemistry & pharmacology

Loading structure…

SMILES

CN1C(=O)CC(C)(C1=O)C2=CC=CC=C2

Mol. weight: 203.2371 g/mol
Lipinski Ro5: Pass
Rule of 3: Yes
Chirality: Racemic Mixture
Inorganic: No
Polymer: No
Delivery: Oral
Availability: Prescription Only

Oral

Yes

Parenteral

Topical

Sources

Also known as

1,3-dimethyl-3-phenyl-2,5-dioxopyrrolidine
1,3-dimethyl-3-phenyl-2,5-dioxopyrrolidine
1,3-dimethyl-3-phenyl-2,5-pyrrolidinedione
1,3-dimethyl-3-phenyl-2,5-pyrrolidinedione
1,3-dimethyl-3-phenyl-pyrrolidin-2,5-dione
1,3-dimethyl-3-phenyl-pyrrolidin-2,5-dione
1,3-dimethyl-3-phenylsuccinimide
1,3-dimethyl-3-phenylsuccinimide
alpha-methyl-alpha-phenyl n-methyl succinimide
alpha-methyl-alpha-phenyl n-methyl succinimide
alpha-methylphensuximide
alpha-methylphensuximide
celointin
celontin
celontin
celontin
celontin
mesuximid
mesuximid
mesuximid
mesuximid
mesuximid
mesuximid
mesuximida
mesuximida
mesuximide
mesuximide
mesuximide
mesuximide
mesuximide
(+/-)-mesuximide
mesuximidum
mesuximidum
mesuximidum
methsuximid
methsuximid
methsuximid
methsuximide
methsuximide
methsuximide
methsuximide
methsuximide
methsuximide
methsuximide
methsuximide
methsuximide
methsuximide, (-)-isomer
methsuximide, (+-)-isomer
methsuximide, (+)-isomer
metosuccimmide
metosuccimmide
metsuccimide
metsuccimide
n,2-dimethyl-2-phenylsuccinimide
n,2-dimethyl-2-phenylsuccinimide
n,2-dimethyl-2-phenylsuccinimide
n-methyl-alpha-methyl-alpha-phenylsuccinimide
n-methyl-alpha-methyl-alpha-phenylsuccinimide
parke david brand of methsuximide
petinutin
pfizer brand of methsuximide
racemic methsuximide
(rs)-1,3-dimethyl-3-phenyl-2,5-pyrrolidindion
(rs)-1,3-dimethyl-3-phenyl-2,5-pyrrolidindion
warner-lambert brand of methsuximide

Organizations

Marketing (4)

Organization	Org type	Relationship	Date
Ani Pharmaceuticals	For profit	MKTG	May 1, 2023
Novitium Pharma	For profit	MKTG	May 1, 2023
Parke-Davis	For profit	NDA	—
Parke-Davis	For profit	SYN	Feb 8, 1957